Insulin resistance is not simply a willpower issue it is a signaling issue
Due to the fact that GLP-1 acting drugs such as dulaglutide, liraglutide, and semaglutide do not need dosage adjustments for patients with renal impairment, these medications are considered to be the most recommended choices for patients who have chronic kidney disease (Zheng et al
The medications are protected by patents, and generic formulations are not expected in the near future
Most are mild to moderate, hit hardest during dose escalation, and improve at stable doses
Some people respond better to semaglutide, and the side effect profiles differ slightly
By maintaining open communication with your medical team, you can navigate the complexities of GLP-1-related hair loss and work towards a solution that supports both your weight management and hair health goals